Do you think there would be benefit in using sparsentan over irbesartan for FSGS given a higher percentage of patients with partial remission of proteinuria on sparsentan despite no significant difference in eGFR slope in the DUPLEX Trial?

Do you think approval of drugs to treat glomerular diseases such as FSGS should be based on change in the eGFR slope?

• Yes, change in eGFR slope in the study data is critical to demonstrate before approval of a drug.
• No, surrogate outcomes such as proteinuria reduction alone should be sufficient for drug approval.
• Yes, however, provisional approval of the medication is reasonable while longer term data is collected on eGFR differences if a surrogate outcome such as proteinuria reduction is achieved in the trial data.
• Other